Showing 1–3 of 3 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Padmapriyadarsini Chandrasekharan
…or shorter, tolerable and effective regimen Hence modified BPaL regimen is designed to study the newer shorter oral in varying doses of Linezolid for pre XDR Tb patients and MDR TI/NR patients The regimen proposed is based on the NIX-TB and ZeNIX trial regimen with modification…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…ies and a longer duration than drug-sensitive tuberculosis. Pre-XDR and XDR-TB are highly DR-TB with a lower success treatment than MDR-TB. Therapy for high DR-TB with fewer drugs and shorter treatment is required to increase the success of treatment. We comprehensively reviewed …
Neela D. Goswami, Lakshmi Praveena Peddareddy, John Jereb, Angel Colon Semidey, Elaine Darnall, et al.
… U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In the study supporting …